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Abstract
Background: Observational studies have consistently shown that aspirin and non-steroidal anti-
inflammatory drug (NSAID) use is associated with a close to 50% reduced risk of colorectal cancer.
Studies assessing the effects of NSAIDs on other cancers have shown conflicting results. Therefore,
we conducted a meta-analysis to evaluate the relationship between NSAID use and cancer other
than colorectal.
Methods: We performed a search in Medline (from 1966 to 2002) and identified a total of 47
articles (13 cohort and 34 case-control studies). Overall estimates of the relative risk (RR) were
calculated for each cancer site using random effects models.
Results: Aspirin use was associated with a reduced risk of cancer of the esophagus and the
stomach (RR, 0.51; 95%CI (0.38–0.69), and 0.73; 95%CI (0.63–0.84)). Use of NSAIDs was similarly
associated with a lower risk of esophageal and gastric cancers (RR,0.65; 95% CI(0.46–0.92) and
RR,0.54; 95%CI (0.39–0.75)). Among other cancers, only the results obtained for breast cancer
were fairly consistent in showing a slight reduced risk among NSAID and aspirin users (RR, 0.77;
95%CI (0.66–0.88), and RR, 0.77; 95%CI (0.69–0.86) respectively)).
Conclusions: The results of this meta-analysis show that the potential chemopreventive role of
NSAIDs in colorectal cancer might be extended to other gastrointestinal cancers such as
esophagus and stomach. Further research is required to evaluate the role of NSAIDs at other
cancers sites.
Background
People who have regularly taken aspirin or other non-ster-
oidal anti-inflammatory drugs (NSAIDs) are at a reduced
risk of developing or dying from colorectal cancer [1–3].
The association with other types of cancer remains
unclear. Animal studies have shown a protective effect of
these drugs in colon [4], esophagus [5], stomach [6,7],
pancreas [8], breast [9,10], prostate [11], lung [12], and
bladder cancer [13], suggesting a common mechanistic
effect of NSAIDs in all these different cancers.
NSAIDs could reduce the risk of cancer through the inhi-
bition of cyclooxygenase-2 (COX-2) [14], the enzyme that
is responsible for the production of various
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prostaglandins. Prostaglandins play a key role on the
accelerated proliferation of tumor tissue. Furthermore
there is mounting evidence that NSAIDs may have the
ability to restore apoptosis and inhibit angiogenesis [15].
If this proposed protective mechanism of NSAIDs is valid,
the preventive effect of NSAIDs could extend to other
human cancers. To date, epidemiological studies in cancer
other than colorectal are scarce and offer inconsistent
results.
The primary aim of our analysis is the use of meta-analyt-
ical techniques to evaluate the effect of aspirin and non-
aspirin NSAIDs (NA-NSAIDs) on cancer sites other than
the colon and rectum. We present summary estimates for
the effect of these drugs in cancer sites where at least two
epidemiological studies could be found.
Methods
Our search included original articles indexed in Medline
from January 1966 to December 2002. We searched for
different common terms used to refer to non-steroidal
anti-inflammatory drugs ("NSAIDs", "anti-inflammatory
drugs") or specific drug names such as "aspirin". Similarly
we used different terms referring to cancer ("neoplasm",
"malignancies", and the prefix "carcino-"). Additionally
we included references cited in original or review articles
that were not included in our original list. We restricted
our search to studies performed in humans and published
in English or Spanish. We individually reviewed all the
abstracts and obtained those articles that satisfied our
inclusion criteria: cohort or case-control studies studying
the association between NSAIDs and cancer other than
colorectal, and reporting an estimate of association such
as relative risk (RR) with confidence intervals or enough
information to compute it. Forty-nine articles were con-
sidered to meet our inclusion criteria. After review by two
of the authors, two of these articles were excluded. The
reasons for exclusion were absence of a control group
[16], invalid exposure and outcome ascertainment [17]. A
total of forty-seven eligible studies were finally identified.
Two of the authors participated in the data extraction
process using a standardized form. Data regarding study
design, analyses and results were entered into a database.
The fields extracted included study design, year of publi-
cation, country, matching used, percentage of response,
exposure assessment, exposure definition, lag time
between exposure and outcome, prevalence of exposure,
outcome assessment, and RR with 95% confidence inter-
vals (CI). We assumed that the odds ratio (OR) from case-
control studies provided a valid estimate for the RR. The
exposures of interest consisted of aspirin, and non-aspirin
NSAIDs (NA-NSAIDs). In this study, the term NSAIDs
refers to either aspirin and/or NA-NSAIDs. Some studies
included paracetamol in the NSAID and/or NA-NSAID
groups. Most studies reported a definition of regular use
(n = 34) and whenever available the estimate for this
exposure was the one extracted. When no clear definition
of regular use was provided (n = 13), we extracted the
most mechanistically meaningful estimate after reaching
consensus between authors in all instances. A total of nine
studies reporting estimates for multiple endpoints con-
tributed to more than one cancer site. We explored all
nine cancer sites for which two or more eligible studies
were found. In the case of cancer of the esophagus we
focused on adenocarcinoma when more than one histo-
logical type was studied.
We fit a DerSimonian and Laird random effects model
[18] to obtain overall estimates for the effects of aspirin,
NA-NSAIDs and NSAIDs in each specific cancer site using
STATA software. This model is more robust than the fixed
effects model and incorporates into the weighting scheme
both the within-study and among-study variance. Hetero-
geneity was explored using Q test statistic [18] in sets
where three or more studies were available. When the
result from this test reached statistical significance we fur-
ther assessed to what extent different study characteristics
could explain the heterogeneity with meta-regression. We
explored potential publication bias qualitatively and
quantitatively using funnel plots and kendall's tau rank
correlation tests [19].
Results
Studies characteristics
Among the 47 studies analyzed [20–66], 13 were cohort
and 34 were case-control studies. Seventeen of the case-
control studies were population based (either nested in a
cohort or using methods like random digit dialing to
ensure that controls are a sample of the underlying cohort
that gave rise to the
cases)[21,22,24,27,28,30,36,39,44,54,59–61,63–66]
whereas the other seventeen were hospital based (using
non-cancer hospital controls) [23,26,32–
35,37,38,42,45,47–49,51,53,55,56,62]. Regarding expo-
sure assessment, most studies (n = 22) used personal
interview typically performed by trained personnel
[22,24–26,28,30–34,38,41–
43,45,47,51,56,60,63,65,66]. Thirteen studies used
mailed questionnaires
[21,23,27,29,39,40,46,50,52,54,56,58,64] and six used
in-hospital questionnaires [35,37,48,49,53,55]. The rest
used either automated databases (n = 4)[20,36,44,61] or
medical records (n = 2) [59,62]. Exposure definition was
very heterogeneous across the different studies and
attempts to categorize it in a few groups for further analy-
sis were unsuccessful. It ranged from more than 6 tablets
per day to ever use of NSAIDs in the 30 days prior to start
date. Prevalence of exposure among controls or cohortBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/28
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members ranged from 4 to 42 percent for NSAIDs
(median, 8 percent), from 2 to 64 percent for aspirin
(median, 16 percent), and from 3 to 46 percent for NA-
NSAIDs (median, 12 percent).
Some studies incorporated the concept of lag time into
their exposure definition (time period before the index
date that was discounted for assessing the exposure sta-
tus). This is mainly motivated by the belief that early
symptoms of the disease (cancer in this case) in the sub-
clinical phase (latent period) might induce or contra-indi-
cate the use of NSAIDs (protopathic bias) [44,67]. Nine
studies used a lag time of 1 year, one study used 1 year and
a half, and two studies used 2 years.
All but ten case-control studies used matched designs (fre-
quency matched (n = 12) or individually matched (n =
12)). Among the individually matched seven studies con-
sidered the matching in the analysis and five did not. All
studies used newly diagnosed cancer as the primary end-
point except for studies by Thun et al and Suleiman et al
that used fatal cancer as outcome.
Most studies were published after 1997 (n = 33). The rest
were published in 1996 (n = 3), 1995 (n = 4), 1994 (n =
1), 1993 (n = 2), 1989 (n = 1), 1988 (n = 1), 1985 (n = 1)
and 1980 (n = 1). The majority of the studies were con-
ducted in North America (USA (n = 32) or Canada (n =
2)). Ten studies were conducted in Europe (U.K. (n = 4),
Greece (n = 2), France (n = 1), Italy (n = 1), Russia (n = 1),
and Sweden (n = 1)), one study in Australia and one study
in New Zealand. Additionally, there was one multicen-
tered international study.
Tables 1 through 9 show the exposure definition, expo-
sure assessment, study type, and the estimates of associa-
tion for each individual study according to the cancer site.
Table 10 summarizes the results by type of drug and can-
cer site. The pooled RR estimates for esophagus and stom-
ach showed a significant protective effect of NSAIDs in the
range of a 40 percent reduction. Aspirin but not NA-
NSAIDs appeared to be associated with a reduced pan-
creas cancer incidence around 30 percent (although this
result was not significant). Breast cancer was the only
other site where results were rather consistent in showing
a protection ranging around a 20 percent reduction.
Results obtained for other studied cancer sites, i.e. ovary,
prostate, bladder, and lung were compatible with no
effect or a possibly slight reduced risk. The result for kid-
ney cancer is compatible with no effect or possibly a slight
increased risk.
Studies assessing the effect of aspirin and other NSAIDs
on cancer of the esophagus were consistent in finding a
protective effect regardless of the study design or exposure
assessment. Among the eight studies identified none
yielded a point estimate larger than 0.85 independently of
the exposure category (see table 1). All but one of the
individual estimates of the effect of aspirin and other
NSAIDs on the risk of developing gastric cancer were
Table 7: Lung
Author Cases N Controlsa/
Cohortb
Source 
Population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Langman et al. 
[36]
2,560 7,643a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs 
(7%)
0.84 0.69–1.02
Harris et al. [51] 489 978a Hospital 
based
>7 tablets per week during more 
than 2 years
Personal 
Interview
NSAIDs(26%) 0.32 0.23–0.44
Akhmedkhanov 
et al[54]
81 808a Population 
based‡
>2 tablets per week during at least 
6 months. 1 year lag time
Mailed 
Questionnaire
Aspirin (19%) 0.66 0.34–1.28
Moysich et al. 
[55]
868 935a Hospital 
based
>1 tablet per week for at least 1 
year
In hospital 
Questionnaire
Aspirin (18%) 0.57 0.41–0.78
Rosenberg[56] 1,110 4,906a Hospital 
based
>3 days/week for >3 months 1.5 
years of lag time
Personal 
Interview
NSAIDs (6%) 1.0 0.7–1.4
Paganini-Hill et 
al. [40]
111 13,987b Cohort Daily use of aspirin for an 
undefined time
Mailed 
Questionnaire
Aspirin (16%) 0.92§ 0.54–1.55
Thun et al. [46]† NR men 290,681b Cohort More than 16 times per month for 
at least one year
Mailed 
Questionnaire
Aspirin (11%) 1.11 0.98–1.25
NR 
women
344,350b 1.07 0.88–1.30
Schreinemachers 
et al. [43]†
163 12,668b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (59%) 0.68 0.49–0.94
Prevalence of exposure among controls/cohort; †Respiratory (includes others); §Crude estimate calculated from data provided in the original 
manuscript; ‡Female population.
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Table 8: Bladder
Author Cases N Controlsa/
Cohortb
Source 
Population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Castelao et al. 
[25]
1,514 1,514a Population 
based
>2 days/week for >1 month Personal 
Interview
Aspirin 
(12%) †
0.85 0.66–1.09
NSAIDs 
(39%)
0.81 0.68–0.96
Langman et al. 
[36]
1,041 3,122a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (7%) 1.14 0.85–1.53
Rosenberg[56] 1,110 4,906a Hospital 
based
>3 days/week for >3 months 1.5 
years of lag time
Personal 
Interview
NSAIDs (6%) 0.8 0.4–1.6
Paganini-Hill et 
al. [40]
93 13,987b Cohort Daily use of aspirin for an 
undefined time
Mailed 
questionnaire
Aspirin (16%) 1.10§ 0.65–1.85
Schreinemachers 
et al. [43]
35 12,668b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (59%) 1.06 0.54–2.09
Prevalence of exposure among controls/cohort; †Exclusive users of aspirin.
Table 9: Kidney
Author Cases N Controlsa/
Cohortb
Source 
Population
Exposure definition Exposure 
assessment
Drug RR 95% CI
McLaughlin et al. 
[63]
495* 697a Population 
based
More than 14 times per month 
for >36 months
Personal 
Interview
Aspirin 
(8%)
0.5† 0.2–1.0
1.8‡ 0.7–4.1
McCredie et al. 
1988[64]
360* 985a Population 
based
>0.1 kg lifetime use Mailed 
questionnaire
Aspirin (18%) 1.2 0.7–1.9
McCredie et 
al.1995[65]
1,732* 2,309a Population 
based
>5 kg lifetime use Personal 
Interview
Aspirin (5%) 1.2 0.9–1.7
Gago-
Dominguez et al. 
[66]
1,201* 1,204a Population 
based
Two or more times a week for 1 
month or longer
Personal 
Interview
Aspirin (27%) 1.5 1.2–1.8
Paganini-Hill et 
al. [40]
NR* 13,987b Cohort Daily use of aspirin for an 
undefined time
Mailed 
Questionnaire
Aspirin (16%) 6.3 2.0–20.0
Schreinemachers 
et al. [43]
32 12,668b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (59%) 0.60 0.29–1.24
*Renal cell carcinoma only;  Prevalence of exposure among controls/cohort; †Male only; ‡Female only.
Table 10: Overall relative risks and 95% confidence interval according to cancer site and type of exposure
N† NSAIDs RR 
(95%CI)
N Aspirin RR 
(95%CI)
NN A - N S A I D s  R R  
(95%CI)
Esophagus 4 0.65 (0.46–0.92) 4 0.51 (0.38–0.69)
Stomach 3 0.54 (0.39–0.75) 5 0.73 (0.63–0.84) 2 0.91 (0.66–1.25)
Pancreas 2 1.09 (0.59–2.01) 3 0.69 (0.40–1.20)
Breast 9 0.77* (0.66–0.88) 11 0.77 (0.69–0.86) 5 0.86 (0.73–1.00)
Ovary 6 0.74 (0.61–0.90) 6 0.91 (0.79–1.06)
Prostate 4 0.64* (0.34–1.21) 7 0.92 (0.81 – 1.05) 2 0.84 (0.68–1.05)
Kidney 6 1.23* (0.86–1.75)
Bladder 3 0.91 (0.71–1.18) 3 0.91 (0.73–1.13)
Lung 3 0.65* (0.34–1.22) 5 0.84* (0.66–1.07)
*p < 0.05 (Heterogeneity test); †Number of studies.
>
>
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smaller than one. Among the five studies evaluating the
effect of aspirin on the risk of gastric cancer, all of them
showed a protective effect. In three out of these five stud-
ies confidence intervals did not include the null.
We found a significant amount of heterogeneity for
NSAIDs in two of the cancer sites, breast and prostate, for
aspirin in renal cancer, and for aspirin and NSAIDs in
lung cancer. Nine studies provided data on the association
Table 1: Esophagus
Author Cases n Controlsa
/Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Coogan et al. 
[26]
207 5,833a Hospital 
based
>4 days/week for >3 months. 
Continuing use during 1 year of 
lag time
Personal 
Interview
NSAIDs 
(7%)
0.8 0.5–1.4
Farrow et al. 
[30]
277 687a Population 
based
>1 tablet/week during >6 months. 
1 year lag time
Personal 
Interview
Aspirin (31%) 0.48† 0.32–0.70
279 NA-NSAIDs 
(13%)
0.81† 0.51–1.30
Langman et al. 
[36]
550 1,650a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (8%) 0.64 0.41–0.98
Garidou et al. 
[32]
56 200a Hospital 
based
Chronic intake Personal 
Interview
NSAIDs 
(14%)
0.52† 0.17–1.62
Suleiman et al. 
[59]
56 56a Population 
based
Ever use for >1 year Medical 
records
NSAIDs 
(38%)
0.16 0.03–0.93
Cheng et al. 
[60]
74 74a Population 
based
Ever daily use for >1 month Personal 
Interview
Aspirin (21%) 0.67 0.27–1.63
Funkhouser et 
al.31
15 13,179b Cohort Use 30 days before baseline 
(ocasional)
Personal 
Interview
Aspirin (51%) 0.10 0.01–0.76
Thun et al. [46] 157 635,031b Cohort More than 16 times per month 
for at least one year
Mailed 
questionnaire
Aspirin (11%) 0.59 0.34–1.03
Prevalence of exposure among controls/cohort; †Adenocarcinoma.
Table 2: Stomach
Author Cases n Controlsa
/Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Farrow et al. 
[30]
612 687a Population 
based
>1 tablet/week during >6 months. 
1 year lag time
Personal 
Interview
Aspirin 
(31%)
0.76 0.60–0.97
610 NA-NSAIDs 
(13%)
0.79 0.56–1.10
Akre et al. [22] 480 1,055a Population 
based
>30 tablets/month. 2 years lag 
time
Personal 
Interview
Aspirin (3%) 0.8 0.7–1.1
NA-NSAIDs† 1.1 0.6–1.4
Zaridze et al. 
[48]
448 610a Hospital 
based
>2 days/week for >6 months In-hospital 
Questionnaire
Aspirin (14%) 0.60 0.41–0.90
NSAIDs 
(17%)
0.65 0.45–0.93
Langman et al. 
[36]
613 1,837a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (8%) 0.51 0.33–0.79
Coogan et al. 
[26]
250 5,883a Hospital 
based
>4 days/week for >3 months. 
Continuing use during 1 year of 
lag time
Personal 
Interview
NSAIDs (7%) 0.3 0.1–0.6
Thun et al. [46] 266 635,031b Cohort More than 16 times per month 
for at least one year
Mailed 
Questionnaire
Aspirin (11%) 0.53 0.34–0.81
Schreinemachers 
et al. [43]
39 12,668b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (59%) 0.93 0.49–1.74
Prevalence of exposure among controls/cohort; †Exposure definition not provided.
>
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Table 3: Pancreas
Author Cases n Cotrolsa/
Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Coogan et al. 
[26]
491 5,833a Hospital 
based
>4 days/week for >3 months. 
Continuing use during 1 year of 
lag time
Personal 
Interview
NSAIDs 
(7%)
0.8 0.5–1.1
Langman et al. 
[36]
513 1,535a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (7%) 1.49 1.02–2.18
Menezes et al. 
[49]
194 582a Hospital 
based
>1 tablet/week for at least 6 
months
In-hospital 
Questionnaire
Aspirin (44%) 1.00 0.72–1.39
Schreinemachers 
et al. [43]
30 12,668b Cohort Ever use of aspirin in the 30 days 
prior to start date
Mailed 
Questionnaire
Aspirin (59%) 0.67 0.33–1.36
Anderson et al. 
[23]
80 28,283b Cohort >6 times/week at baseline Mailed 
Questionnaire
Aspirin (21%) 0.40 0.20–0.82
NA-NSAIDs 
(NR)
1.28 0.68–2.43
Prevalence of exposure among controls/cohort
Table 4: Breast
Author Cases n Controlsa/
Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Sharpe et al. [44] 5,882 23,517a Population 
based
>2 tablets/week during years 2 – 
5 before index date
Automated 
Database
NSAIDs 
(4%)
0.76 0.63–0.92
Harris et al. [33] 744 767a Hospital 
based
>3 tablets/week during more 
than 5 years
Personal 
Interview
NSAIDs 
(16%)
0.6 0.4–0.8
Harris et al. [34] 511 1,534a Hospital 
based
>3 tablets/week for at least 1 
year
Personal 
Interview
Aspirin (12%) 0.69 0.46–0.99
NSAIDs 
(28%)
0.66 0.52–0.83
Coogan et al. 
[25]
6,558 2,925a Hospital 
based
>4 days/week for >3 months. Personal 
Interview
Aspirin (N.R.) 0.7 0.5–0.8
Continuing use during 1 year of 
lag time
NA-NSAIDs 
(N.R.)
0.8 0.6–1.1
NSAIDs (7%) 0.7 0.6–0.8
Langman et al. 
[36]
3,105 9,772a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (6%) 1.10 0.92–1.30
Cotterchio et al. 
[27]
3,133 3,062a Population 
based
Daily use for more than two 
months. 1 year before start date 
excluded
Mailed 
Questionnaire
Aspirin (14%) 0.73 0.61–0.87
NA-NSAIDs 
(11%)
0.79 0.66–0.96
NSAIDs 
(26%)
0.76 0.66–0.88
Meier et al. [61] 3,706 14,155a Population 
based
≥30 prescriptions Automated 
Database
NSAIDs (8%) 1.0 0.8–1.1
Rosenberg et al. 
[56]
4,485 4,906a Hospital 
based
>3 days/week for >3 months 1.5 
years of lag timev
Personal 
Interview
NSAIDs (6%) 0.8 0.6–1.0
Neugut et al. 
[62]
252 176a Hospital 
based
Chronic aspirin use Medical 
Records
Aspirin (9%) 0.80 0.35–1.80
Friedman et al. 
[20]
NR 143,574b Cohort ever use Medical 
Records
Aspirin‡ (2%) 0.20 0.05–0.80
NA-NSAIDs» 
(3%)
0.50 0.28–0.88
Johnson et al. 
[58]
938 27,616b Cohort >5 times per week Mailed 
questionnaire
Aspirin (21%) 0.71 0.58–0.87
>
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between NSAID use and breast cancer incidence. The
overall estimate for this effect was 0.77 (95% CI, 0.66–
0.88) and significant between-study variation was found.
Study design (hospital based case-control, population
based case-control, or cohort study) and exposure assess-
ment appeared to be the variables that explained hetero-
geneity to a greater extent in the meta-regression. The
pooled estimate for hospital based case-control studies (n
= 4) was 0.69 (95%CI,0.62–0.77) whereas the pooled
estimate for population based case-control studies (n = 4)
NA-NSAID 
(13%)
1.01 0.83–1.25
Egan et al. [29] 2,414 89,528b Cohort >2 tablets/week reported in 4 
consecutive questionnaires
Mailed 
Questionnaire
Aspirin (15%) 1.01 0.80–1.27
NA-NSAIDs 
(4%)
0.95 0.78–
1.17†
Harris et al. [35] 393 32,505b Cohort >4 tablest/week at start date In-hospital 
Questionnaire
Aspirin (13%) 0.64 0.45–0.90
NSAIDs 
(25%)
0.57 0.44–0.74
Paganini-Hill et 
al. [40]
214 8,881b Cohort Daily use of aspirin for an 
undefined time
Mailed 
Questionnaire
Aspirin (15%) 1.05§ 0.73–1.50
Thun et al. [46] NR. 344,350b Cohort More than 16 times per month 
for at least one year
Mailed 
Questionnaire
Aspirin (11%) 0.88 0.62–1.24
Schreinemachers 
et al. [43]
147 7,489b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (64%) 0.70 0.50–0.96
Prevalence of exposure among controls/cohort; §Crude estimate calculated from data provided in the original manuscript; † For NA – NSAIDs 
only the baseline questionnaire was considered; ‡ includes only Fiorinal (aspirin, phenacetin, caffeine and butalbital combination); » indomethacin 
only.
Table 5: Ovary
Author Cases n Controlsa/
Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Tzonou et al. 
[47]
189 200a Hospital 
based
>2 tablets/week Personal 
Interview
NSAIDs 
(26%)
0.51 0.26–1.02
Cramer et al. 
[28]
563 523a Population 
based
>1 tablet/week for >6 months. 1 
year lag time.
Personal 
Interview
Aspirin†(14%) 0.75 0.52–1.10
NSAIDs‡ (7%) 0.91 0.53–1.54
Tavani et al. 
[45]
749 898a Hospital 
based
>1 tablet/week for >6 months. 
(current and/or former)
Personal 
Interview
Aspirin (6%) 0.93 0.53–1.62
Rosenberg[56] 448 4,906a Hospital 
based
>3 days/week for >3 months 1.5 
years of lag time
Personal 
Interview
NSAIDs (6%) 0.8 0.5–1.3
Rosenberg et al. 
[42]
780 2,570a Hospital 
based
>4 days/week for at least 6 
months.1 year lag time
Personal 
Interview
Aspirin (5%) 0.8 0.5–1.2
NA-NSAIDs 
(3%)
0.5 0.3–1.0
NSAIDs (8%) 0.7 0.5–1.0
Moysich et al. 
[37]
547 1,094a Hospital 
based
>1 day/week for 6 consecutive 
months
In-hospital 
Questionnaire
Aspirin (12%) 1.00 0.73–1.39
Akhmedkhanov 
et al. [21]
68 680a Population 
based
Ever use of >3 tablet/week for 
>6 months. 1 year lag time
Mailed 
Questionnaire
Aspirin (16%) 0.60 0.26–1.38
Meier et al. [61] 483 1,877a Population 
based
≥30 prescriptions. 1 year lag time Automated 
Database
NSAIDs (5%) 1.1 0.6–1.8
Fairfield et al. 
[50]
333 76,821b Cohort >1 tablet/week Mailed Aspirin (46%) 1.00 0.80–1.25
NSAIDs 
(N.R.)
0.60 0.38–0.95
Prevalence of exposure among controls/cohort; †Over-the-counter only; ‡Prescription only.
Table 4: Breast (Continued)
>
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was 0.89 (95% CI, 0.74–1.08). There was only one cohort
study (RR, 0.57;95%CI,0.44–1.73). Regarding exposure
assessment, only two studies used mailed questionnaires
to ascertain NSAID exposure. The combined estimate for
these studies was 0.67 (95%CI, 0.51–0.89). For studies
using personal interview as exposure assessment method
(n = 4) the overall estimate was similar (RR,0.69;
95%CI,0.62–0.77). The other three studies used auto-
mated databases to elicit exposure and they found little or
no effect (RR,0.95;95%CI,0.77–1.16). Once we adjusted
for exposure assessment, study design did not explain
additional heterogeneity. We found that the protective
effect of NSAID use was slightly stronger among studies
not using lag time (n = 3) (RR,0.69;95%CI,0.51–0.94)
than among those using lag time (n = 5) (RR, 0.81;
95%CI,0.69–0.96). It is somewhat difficult to draw con-
clusions about possible sources of heterogeneity in the
other two cases (prostate, kidney and lung) due to the lim-
ited number of studies.
Discussion
This meta-analysis attempts to evaluate the effectiveness
of NSAIDs in reducing the risk of cancer other than color-
ectal as primary prevention. Based on a limited number of
studies, the results show that NSAIDs overall and aspirin
in particular are associated with a decreased risk of devel-
oping both esophageal cancer and gastric cancer with a
magnitude of effect (40 % reduction) comparable to the
one observed with colorectal cancer. A recently published
meta-analysis addressing esophageal cancer found similar
results [68]. The results for breast are consistent in
showing a slight protection. Overall results for the effect
of aspirin on pancreatic cancer show a non-significant risk
reduction, while results from ovary, prostate, kidney,
bladder and lung cancer are compatible with no effect of
NSAIDs in preventing these cancers.
The association with NSAIDs has been extensively studied
for colorectal cancer through observational methods and
it is now pending confirmation on the results of experi-
mental studies currently ongoing for secondary preven-
tion [69]. If the observed association in colorectal cancer
were true, one could expect a similar effect in other can-
cers of the gastrointestinal tract. The consistency observed
in the results for esophageal and gastric cancer in our
meta-analysis tends to support this hypothesis. Unfortu-
Table 6: Prostate
Author Cases n Controlsa/
Cohortb
Source 
population
Exposure definition Exposure 
assessment
Drug RR 95% CI
Nelson et al. [38] 417 420a Hospital 
based
>1 tablet/day in the year prior to 
admission
Personal 
Interview
NSAIDs 
(15%)
0.34 0.20–0.58
Langman et al. 
[36]
1,813 5,354a Population 
based
>7 prescriptions during months 
13–36 before index date
Automated 
Database
NSAIDs (7%) 1.33 1.07–1.64
Norish et al. [39] 317 480a Population 
based
>1 tablet/week Mailed 
Questionnaire
Aspirin (29%) 0.85 0.61–1.19
NA-NSAIDs 
(7%)
0.87 0.49–1.55
NSAIDs 
(36%)
0.88 0.64–1.20
Irani et al. [53] 639 659a Hospital 
based
Ever use In-hospital 
Questionnaire
NA-NSAIDs 
(46%)
0.80 0.66–1.07
Neugut et al. 
[62]
319 189a Hospital 
based
Chronic aspirin use Medical 
records
Aspirin (7%) 1.60 0.82–3.11
Roberts et al. 
[41]
91 1,362b Cohort Daily use Mailed 
Questionnaire
NSAIDs 
(42%)
0.37 0.22–0.62
Paganini-Hill et 
al. [40]
149 5,106b Cohort Daily use of aspirin for an 
undefined time
Mailed 
Questionnaire
Aspirin (17%) 0.94§ 0.61–1.44
Thun et al. [46]† N.R. 290,681b Cohort More than 16 times per month 
for at least one year
Mailed 
Questionnaire
Aspirin (11%) 0.82 0.56–1.19
Schreinemachers 
et al. [43]
123 5,179b Cohort Ever use of aspirin in the 30 days 
prior to start date
Personal 
Interview
Aspirin (51%) 0.95 0.66–1.35
Leitzmann et al. 
[52]
2,479 47,882b Cohort ≥2 tablets per week reported in 
4 consecutive questionnaires
Mailed 
Questionnaire
Aspirin (N.R.) 1.04 0.86–1.26
Habel et al. [57] 2,574 90,100b Cohort >6 tablets almost ever day In hospital 
Questionnaire
Aspirin (2.7%) 0.76 0.60–0.98
Prevalence of exposure among controls/cohort; §Crude estimate calculated from data provided in the original manuscript; †Genital (includes 
prostate and testis).
>
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nately, very few studies assessed whether contraindication
for use of aspirin and NA-NSAIDs could explain the
observed protective effect. It is most likely true that
patients with upper gastrointestinal symptoms or disease
are likely to use less NSAIDs than the general population,
and these conditions are positively correlated with the
occurrence of both esophageal and gastric cancer.
Overall results for the effect of aspirin on pancreatic can-
cer show a non-significant risk reduction around 30%.
While the two cohort studies show a strong protective
effect (close to 50% reduction)[23,43] a recently pub-
lished case-control study shows no effect [49].
The results for breast are consistent in showing a slight
protection (around 20%). However, as we previously
indicated, results from other sites (ovary, prostate, kidney,
bladder and lung cancer) are compatible with no effect of
NSAIDs in preventing these cancers. This seems to con-
firm the idea that NSAID primary prophylaxis for cancer,
far from being the new panacea, has limited results and
restricted to some cancers mainly in the gastrointestinal
area[70,71] although evidence for other cancers is sparse
and would require additional studies to have a more
robust estimate of the true association.
Phenacetin-containing analgesics have been shown to
increase renal cancer [72], and it is unclear whether this
effect is common to NSAIDs. Our result on cancer of the
kidney cannot exclude a slight increased risk associated
with aspirin use. However caution must be taken when
interpreting these results. Phenacetin was commonly used
in combination with aspirin, so the studied effect of
aspirin often combines the effect of aspirin and phenace-
tin given together [73]. The results for prostate cancer are
not compatible with an increased risk of NSAIDs, which
seems to support the hypothesis that the elevated risk
observed in some studies might result from detection bias.
In table 10 the estimate for the overall effect of NSAIDs on
gastric cancer is not the weighted average of the corre-
sponding estimates of aspirin and NA-NSAIDs. This is due
to the fact that none of the studies assessed simultane-
ously the three different types of drug exposure and there-
fore estimates for each type of NSAID arise from different
studies with different characteristics.
Tests for heterogeneity found a significant amount of
between-study variance in four of the combined esti-
mates. One problem with these tests is that they are not
sensitive enough when a small number of studies is being
pooled. Consequently, caution must be taken when
interpreting these results. However, the use of a random
effects model takes into account to certain extent this
additional source of variability and incorporates it in
obtaining the pooled estimate. Our analysis found signif-
icant heterogeneity among the studies addressing the
association between NSAIDs and breast cancer. Further
analysis of this variation showed that among case-control
studies, hospital based studies yielded a more optimistic
result than population-based. Two key features that define
the quality of a case-control study are the selection of con-
trols and the way in which the exposure is ascertained.
Controls in hospital-based studies rarely attain to be a true
representative sample from the source population where
cases have arisen. This is especially troublesome when the
reason for admission could be related to the exposure,
which represents the greatest limitation of this study
design [74]. On the other hand, controls in population-
based studies tend to give a more valid estimate of the
exposure in the source population. The method used to
elicit the exposure will also determine the quality of the
data. Automated databases (AD) offer some advantages
when long term drug exposure is to be ascertained. In con-
trast to personal interviews or self-administered question-
naires that rely heavily on the subject's ability to recall, AD
provide detailed information on dates of use and type of
drugs used. Furthermore this information is equally good
for cases or controls irrespective of the event of interest
since it was recorded prospectively (as opposed to meth-
ods based on subject's ability to recall which may depend
on the case status). We found that the estimate for the sub-
set of studies using AD was more conservative than the
estimates for studies using personal interviews or mailed
questionnaires. On the other hand, the downside of using
ADs in assessing NSAID exposure is its inability to capture
exposure to widely available over-the-counter NSAIDs.
This could result in non-differential misclassification of
exposure that would dilute the underlying effect, and rep-
resents an alternative explanation for the more conserva-
tive results obtained in the AD subset.
One possible explanation of RR heterogeneity is variation
in background rate. This ought to be addressed by
considering the background rates in study populations
exhibiting heterogeneity. However, most of the popula-
tion based case-control studies did not report incidence
rates (or enough information to compute) and there were
a limited number of cohort studies. Therefore we were
unable to assess the influence of different background
rates.
The limited number of studies involved in the estimates
for the effects of aspirin on lung cancer and NSAIDs on
prostate cancer prevents us from a conclusive analysis of
the source of heterogeneity observed in these estimates.
Exposure definition in all the reviewed studies was quite
heterogeneous. According to the proposed mechanism,
chronic exposure to NSAIDs would be needed in order toBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/28
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observe the hypothesized protective effect. However, we
found that studies using relatively broad exposure defini-
tions (such as "ever use of aspirin in the 30 days prior to
start date") were able to detect associations similar to the
ones observed in studies with more specific and "valid"
exposure definitions. In general, the consistency in the
results was surprisingly high considering the large amount
of heterogeneity in exposure definition across studies. In
our opinion, this is due to the fact that, in these popula-
tions, different exposure definitions are still highly corre-
lated (i.e. subjects classified as exposed by "loose"
exposure definitions have still a relatively high probability
of being chronic users as compared to the ones called non
users). This, somehow, justifies pooling these studies to
obtain an overall estimate. However, this correlation
between different exposure definitions will be different
between aspirin and NA-NSAIDs. Since the relative preva-
lence of chronic use is greater among aspirin users (as a
result of its predominant use for prevention of cardiovas-
cular disease) than among NA-NSAID users, this grouping
of exposure would result in a greater misclassification
among NA-NSAID users than aspirin users. This might
partly explain the closer to the null results obtained for
NA-NSAIDs though the number of individual studies
were too limited to analyze this with confidence. Overall
prevalence of NSAID exposure among the controls/cohort
was quite variable across studies. Based on a qualitative
review, we could say that it was a function of both the
nature of the study population and the looseness of the
exposure definition applied. It is noteworthy that studies
that reported abnormally low or high prevalence of expo-
sure (inversely related to studies using AD) tended to find
extreme results in both directions.
Protopathic bias could overestimate exposure among
cases in those studies that do not include lag time in their
exposure definition if early symptoms of cancer influ-
enced the subsequent use of NSAIDs. Our analysis did not
identify large differences between studies using and not
using lag time although the latter generally yielded more
conservative results. Also, since the primary endpoint in
most of these studies was clinical diagnosis of cancer, and
given that this endpoint can be associated with screening
frequency, this potential bias deserves consideration. This
is especially true for cancers such as breast or prostate
where screening methods are widely available. Barry
hypothesized that if NSAID use is a proxy for poorer gen-
eral health, one would expect these people to get less
screening and therefore to be less likely to be diagnosed
with cancer [75], but the exact opposite argument can be
made with equal force. At present, most chronic NSAID
use comes from low dose aspirin indicated for
cardioprotection, and people pursuing this prophylactic
measure are likely to be more health-conscious and fol-
low other preventive actions such as timely screening. This
would associate NSAID exposure spuriously with a higher
risk of cancer. Therefore, the net effect of this potential
bias, if any, is difficult to predict.
Some authors have questioned the use of random effect
models arguing that it might not always be more conserv-
ative than the fixed effects model [76]. The use of fixed
effects models in our data resulted in very similar point
estimates and full consistency regarding statistical signifi-
cance (data not shown). We evaluated the potential for
publication bias plotting the log RR from each study
against its standard error as well as using kendall's tau test
and found no substantial evidence of publication bias.
Conclusions
In summary, the results of this meta-analysis show that
the potential chemopreventive role of NSAIDs in colorec-
tal cancer might extend to other gastrointestinal cancers
such as esophagus and stomach. There is evidence that
supports a similar effect, though to a smaller extent, of
NSAIDs in breast cancer whereas such potential in other
cancers appears to be slim based on the reviewed litera-
ture. In general, the extent to which this potential benefit
might be offset by the adverse effects of long-term use of
these drugs is not clear especially in cancers with low inci-
dence and clearly needs to be taken into account when
evaluating the chemoprophylactic role of NSAIDs. The
role of a new class of NSAIDs such as selective COX-2
inhibitors is yet to be assessed as well as the optimal dose
and duration regimen for a hypothetical prevention ther-
apy. Further research is required to solve all these open
and important questions.
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